Flash FinanceUS
Market closed · weekend S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Vertex Pharmaceuticals (VRTX)

Vertex names Jonathan Poole CFO, effective January 1, 2027

Neutral Impact 4 of 5 leadership Written later

Vertex Pharmaceuticals appointed Jonathan Poole as Executive Vice President and Chief Financial Officer on August 27, 2026, effective January 1, 2027. Charles F. Wagner, Jr. will stop serving as CFO on that date but will remain Executive Vice President and Chief Operating Officer. The filing discloses Mr. Poole's salary, bonus target and severance terms, which shareholders may review in the 10-Q exhibits later.

Key points

  • Jonathan Poole, 51, becomes EVP and CFO effective January 1, 2027, having been Senior Vice President, Finance at Vertex since March 2020
  • Charles F. Wagner, Jr. ceases to be CFO on the effective date and remains EVP and Chief Operating Officer
  • Poole's base salary is $750,000, with a target annual bonus of 90% of base salary
  • Severance on termination without cause or for good reason is 100% of base salary and target bonus; the change of control agreement covers the period from 90 days before to 12 months after a change of control

The filing

CompanyVertex Pharmaceuticals (VRTX)
Form8-K, current report
Filed with the SECSep 1, 2026, 4:25 PM ET
Accession number0000875320-26-000264

Items reported: 5.02 Director / Officer Change

Read the filing on SEC.gov ↗

Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 8, 2026, 2:16 AM ET, from the text of the filing and its press-release exhibits only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on September 01, 2026.

Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.